サインイン 無料でサインアップします。

PureTech Health PlcのROCE

PureTech Health PlcのROCEは何ですか。

PureTech Health PlcのROCEは0.00%です。

ROCEの定義は何ですか。



使用資本利益率(ROCE)は、企業の収益性とその資本が使用される効率を測定する財務比率です。

Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.

ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.

Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.

LSEのセクタHealth CareにおけるROCEの企業と比べるPureTech Health Plc

PureTech Health Plcは何をしますか。

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

PureTech Health Plcと類似のroce